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Phage therapy involves the application of lytic bacteriophages for treatment of clinical
infections but bacterial resistance may develop over time. Isolated from nosocomial
infections, small colony variants (SCVs) are morphologically distinct, highly virulent
bacterial strains that are resistant to conventional antibiotics. In this study, SCVs was
derived from Pseudomonas aeruginosa exposed to the lytic bacteriophage PB1 and
these cells were resistant to subsequent phage infection by PB1. To elucidate the
mechanism of the SCV phage resistance, we performed phenotypic assays, DNA
microarrays and whole-genome sequencing. Compared with wild-type P. aeruginosa,
the SCV isolate showed impaired biofilm formation, decreased twitching motility,
reduced elastase and pyocyanin production. The SCV is also more susceptible to the
antibiotic ciprofloxacin and exhibited higher syrface hydrophobicity than the wild-type,
indicative of changes to cell surface lipopolysaccharide (LPS) composition. Consistent
with these results, transcriptomic studies of SCV revealed up-regulation of genes
involved in O-specific antigen (OSA) biosynthesis, suggesting the regulation of surface
moieties may account for phage resistance. Western blot analysis showed a difference
in OSA distribution between the two strains. Simultaneously, genes involved in aromatic
and branched chain amino acid catabolism were down-regulated. Whole genome
sequencing of the SCV revealed multiple single nucleotide variations within the Pf1
prophage region, a genetic locus known to play a crucial role in biofilm formation and
to provide survival advantage via gene transfer to a subpopulation of cells. Insights into
phenotypic and genetic changes in SCV gained here should help direct future studies
to elucidate mechanisms underpinning phage resistance, leading to novel counter
resistance measures.
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INTRODUCTION
The emergence of multidrug-resistant pathogens and the
difficulties in developing new antibiotics have spurred the
resurgence of interest in phage therapy, involving the use of
lytic bacteriophages against specific pathogens as a form of
treatment (DiMasi et al., 2003; Gilbert et al., 2003; Spellberg
et al., 2004; Talbot et al., 2006; Keen, 2012; Ly-Chatain, 2014).
Pseudomonas aeruginosa is an opportunistic pathogen found
ubiquitously in urban and natural environments, e.g., soil, rivers
and sewage. In hospital settings, bacteria colonizes the surfaces
of medical equipment such as catheters, inhalers, nebulizers
and tubings (Stamm, 1978; Kirschke et al., 2003), where they
account for approximately 10% of nosocomial infections (System,
2004). P. aeruginosa have been isolated from urinary tract
and inner ear infections, burn wounds and from the surface
of human epithelia in cystic fibrosis patients (Govan and
Deretic, 1996; Lyczak et al., 2000; Lang et al., 2004; Taneja
et al., 2004). Eradicating P. aeruginosa is not trivial as it has
evolved various resistance mechanisms against conventional
antibiotic therapies (Yoshimura and Nikaido, 1982; Nickel et al.,
1985; Poole, 2004). Phage therapy has thus gained increasing
consideration as an alternative treatment for antibiotic-resistant
bacteria. Currently, phage therapies against methicillin-resistant
Staphylococcus aureus and pathogenic Escherichia coli are in
clinical trials (Harper and Enright, 2011). Studies have been
carried out to elucidate how P. aeruginosa affects animal models
of gut sepsis (Watanabe et al., 2007), burn wound (McVay et al.,
2007) and lung infection (Morello et al., 2011). In one human
clinical trial, Wright et al. (2009) administered a bacteriophage
cocktail to treat chronic otitis. In another, Khawaldeh et al. (2011)
reported the use of a lytic bacteriophage cocktail to treat a human
patient suffering from P. aeruginosa urinary tract infection.
Although these reports indicate that while phage therapy can
be initially effective against P. aeruginosa, spontaneous phage
resistance often occurs afterward, rendering the phage therapy
ineffective.
Small colony variants (SCVs) of infectious strains of bacteria
were first identified in 1910 (Proctor et al., 2006), so named
because the colonies formed by SCVs are one 10th the colony size
of their wild-type counterparts. SCVs exhibit higher antibiotic
resistance than wild-type bacteria and they often form after
exposure to high concentrations of antimicrobial agents such
as gentamicin (Wei et al., 2011). Studies have also showed that
SCVs could be induced in planktonic cultures of P. aeruginosa
in response to infection by the lysogenic filamentous phage Pf4
(Webb et al., 2004; Hui et al., 2014). In the current study, a
phage resistant SCV (F1 strain) of P. aeruginosa PAO1 strain
(F0 strain) was successfully isolated using the lytic phage PB1.
The first PB1 phage was first described in Holloway et al.
(1960). Subsequently, a family of at least 42 other PB1-like
bacteriophages against P. aeruginosa was discovered (Krylov
et al., 1993; Pleteneva et al., 2008; Ceyssens et al., 2009). PB1 and
PB1-like bacteriophages belong to the Myoviridae phage family
and use bacterial lipopolysaccharide (LPS) as their receptor
(Kropinski et al., 1977), and these lytic bacteriophages are a family
of promising agents for phage therapy(Garbe et al., 2010; Krylov
et al., 2013). Phage cocktail containing PB1-like myoviridae
phages are currently use in clinical trials (Kwan et al., 2006;
Merabishvili et al., 2009). The selection pressure imposed by
PB1 phage allowed the isolation of SCVs which produce smaller
colonies than their wild-type counterparts on agar plates. Besides
determining the SCVs’ resistance to subsequent PB1 infections
other characteristics such as their surface hydrophobicity,
pyocyanin production, biofilm formation and cell lengths using
microscopy were determined as well. The gene expression profiles
of both wild-type and SCV P. aeruginosa were studied using
DNA microarrays, and several pathways that could potentially
confer phage resistance in SCV were identified. Whole genome
sequencing enabled identification of point mutations and single
nucleotide polymorphisms in the genome of SCVs that could
have conferred a survival advantage and resulted in other
phenotype changes in the SCVs.
MATERIALS AND METHODS
Bacterial Strains and F1 Strain Isolation
Pseudomonas aeruginosa strain PAO1 (ATCC 47085) was
designated as the wild-type F0 strain in this work. Glycerol
stock of F0 was streaked on LB agar plates supplemented with
10 µg/mL tetracycline and incubated overnight at 37◦C. For
sub-culturing, 1 mL of overnight culture was added to 25 mL
of LB broth diluted with 25 mL of reduced strength LB (20%)
broth and incubated at 37◦C, 225 rpm for all experiments unless
otherwise stated. For phage infection, 500 µL of PB1 phage stock
(1× 1010 PFU/mL) was added to the subculture after allowing the
subculture to recover at 37◦C, 225 rpm for 1 h. Infected cultures
were cultured for 24 h at 37◦C, 225 rpm. The culture was streaked
on fresh LB plates with 10 µg/mL tetracycline and incubated
overnight at 37◦C. The SCV was isolated (F1) for subsequent
experiments.
Determination of the Stability of SCV
Phenotype
Single colonies of F0 and F1 were inoculated in 5 mL LB media
and incubated at 37◦C, 225 rpm for 6 h. The cultures were
streaked onto agar plates and incubated at 37◦C overnight. The
colony size of both F0 and F1 were compared the following day.
The SCV phenotype was determined to be stable as long as the
colony size of F1 remained smaller than that of F0. The process
was repeated for seven passages.
OD600 Measurements, Cell Viability
Assays, Generation Time Determination
and Gram Staining and Microscopy
OD reading was measured at 600 nm using a UV-vis
spectrophotometer in a 1 cm cuvette. Serial dilutions (10−1 to
10−7) of cultures were performed in 0.01% peptone. 100 µL of
10−3 to 10−7 dilutions with duplicates were spread on LB plates
with 10 µg/mL tetracycline. Plates were incubated overnight at
37◦C. Plates with colonies ranging from 25 to 300 were counted
and the numbers obtained averaged. Morphologies on agar plates
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were observed. For the determination of generation time, hourly
OD600 measurements were taken for 7 h and a growth curve
was plotted (not shown). By measuring the gradient for the linear
portion of the plot, the generation time could be determined. For
microscopy studies, F0 and F1 cultures at mid-log were heat fixed
and Gram-stained (Sigma) according to manufacturer’s protocol.
The slides were viewed under a 100X objective with an Eclipse
Ni-U microscope (Nikon) under oil immersion.
Antibiotic Susceptibility Measurement
with Etest
One mililiter of an overnight culture was diluted in 50 mL
of LB media and incubated at 37◦C, 225 rpm for 4 h. The
turbidity of the culture was adjusted with 1X PBS to match that
of MacFarland standard 0.5. Bacterial lawn of F0 or F1 was
streaked onto Mueller-Hinton II agar plates with a cotton swab
and plates allowed to dry for 5 min. An Etest strip (bioMérieux)
containing gentamicin or ciprofloxacin was then placed onto the
agar plate with sterile tweezers and the plates were incubated at
37◦C overnight. The minimum inhibitory concentration (MIC)
readings were read off at the point where the inhibition ellipse
intersects the scale on the strip.
Biofilm Formation Assay
The assay was adapted from the original protocol as described
by Stepanovic´ et al. (2000). A single colony of bacteria was
inoculated in 5 mL Vogel-Bonner medium supplemented with
2% (w/v) glucose and incubated overnight at 37◦C. Two hundred
microliter of the overnight culture was seeded per well into a
96-well plate and the plate was further incubated for 24 h at
37◦C. The culture was carefully aspirated with a pipette and
each well was washed once with 200 µL of 1X sterile phosphate
buffer saline (PBS), pH 7.5. The plate was inverted and dabbed
dry onto paper towels after washing. One hundred and fifty
microliter of methanol was added per well to fix the cells for
7 min and the methanol was then removed by removed by
inverting the plate and gently flicking off any residual liquid. The
plate was then dabbed dry onto paper towels. One hundred and
fifty microliter of crystal violet was added per well to stain the
attached cells for 30 min and the crystal violet was then removed
by inverting and gently flicking the plate. The wells were then
rinsed gently with tap water. The plate was inverted and finally
dabbed dry onto paper towels. The amount of attached cells was
then quantified via the solubilization of the bound crystal violet
through the addition of 150 µL of 33% acetic acid into each well.
The absorbance at 620 nm (A620) was measured using a plate
reader.
Elastase and Pyocyanin Assays
The assay was modified from the procedure given by Kamath
et al. (1998) and Carlsson et al. (2011). Bacteria were grown for
60 h in King’s Medium A (King et al., 1954). Five mililiter of
the overnight culture was centrifuged at 4600 rpm for 5 min at
room temperature and the supernatant was collected and filtered
through a 0.2 µm filter.
To measure the specific activity of elastase, 20 mg of
Elastin-Congo Red (Sigma) substrate was added to 2 mL
of reaction buffer (30 mM Tris-HCl; pH 7.5) in a 15 mL
falcon tube. After warming the mixture to 37◦C, 800 µL of
filtered supernatant was added. The entire mixture was further
incubated at 37◦C, 225 rpm for 2 h. Elastin-Congo Red was
pelleted by centrifugation at 4600 rpm for 10 min and the
OD495 of the supernatant was measured with reaction buffer
as the blank. The background absorbance was determined by
measuring the absorbance of the reaction buffer and filtered
supernatant without Elastin-Congo Red. Measurements were
carried out in triplicate by a Infinite 200 PRO plate reader (Tecan)
and the values were averaged and corrected for background
absorbance. The elastase activity (OD495 hr−1 mL−1) of the
filtered supernatant was calculated by adjusting the corrected
OD495 values for incubation time, reaction volume and
dilution factors. The amount of total protein in the filtered
supernatant was determined with a Bradford assay, using the
Coomassie Plus Assay Kit (Pierce) according to manufacturer’s
instructions. Finally, the specific activity of elastase (OD495 mg
protein−1 h−1) in the supernatant was determined by dividing
the elastase activity with the total protein concentration.
For the measurement of pyocyanin concentration, 2 ml of
chloroform was added to the filtered supernatant and vortexed
for 30 s. The mixture was then centrifuged at 4600 rpm for
10 min to allow complete separation of the aqueous and organic
phases. Eight hundred microliter of the blue chloroform phase
was collected and mixed with 200 µL of 0.2 M HCl before
vortexing for 30 s. One hundred fifty microliter of the pink layer
was added to a 96 well plate and OD520 was measured with
Infinite 200 PRO plate reader (Tecan). OD520 was multiplied by a
factor of 17.072 to obtain the concentration of pyocyanin and the
concentration of pyocyanin in the supernatant was determined
by taking into account of dilution factors.
Twitching Motility and Microbial
Adhesion to Hydrocarbon (MATH) Assays
The twitching assay was carried out as described by Rashid
and Kornberg (2000). Bacteria were stabbed onto twitch agar
plates (1% agar LB plates). Twitch plates were incubated at
37◦C for 48 h. The diameter of the zone of twitching was
measured to estimation bacterial motility. To determine surface
hydrophobicity, the MATH assay was adapted from the work of
Pérez et al. (1998). Bacteria were first grown to mid-log in LB
media. A 4 mL aliquot of the culture was centrifuged at 4600 rpm
for 5 min. The supernatant was discarded and the pellet was re-
suspended in 4 ml of PBS. This aliquot was then sub-divided
into 2 aliquots of 2 ml each. Four hundred microliter of xylene
was added to one of the tubes. Both tubes were vortexed for
2 min before allowing the tubes to stand for 30 min. Subsequently,
1 mL of aqueous phase from each aliquot was added to a cuvette
and the OD OD600 measured (OD0 and ODxylene representing
the OD of the aliquot without and with xylene respectively).
Surface hydrophobicity (H%) was calculated by the percentage
change in turbidity before and after addition of xylene using the
formula: ODxylene−ODoODo × 100
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Statistical Analysis for Phenotypic Assays
The differences between F0 and F1 were assessed with the Mann–
Whitney test (for cell length measurement as the distribution
of cell length are not normally distributed) and the unpaired
Student’s t-test (for all other assays) using GraphPad Prism.
Values are reported as mean ± standard deviation (SD).
P-values < 0.05 were considered statistically significant.
LPS Extraction and Western Analysis
The LPS extraction procedure was modified from that of Davis
and Goldberg (2012). A 5 mL suspension of mid-log culture (OD
0.5) was centrifuged at 4600 rpm for 10 min and the supernatant
was discarded. The bacterial pellet was resuspended in 200 µL
1X SDS buffer (2% β-mercaptoethanol, 2% SDS, 10% glycerol
in 0.1M Tris-HCl pH 6.8, pinch of bromophenol blue) and
boiled for 15 min. The solution was allowed to cool to room
temperature for 15 min and 10 µL of 10 mg/mL Proteinase K
was added. Samples were then incubated at 59oC overnight. Two
hundred microliter of ice cold Tris-saturated phenol was added
and samples were vortexed for 5 s. The mixture was incubated
at 65oC for 15 min with occasional vortexing and then allowed
to cool to room temperature. One mililiter of diethyl ether was
added and vortexed for 5 s centrifuging at 20,600 g for 10 min.
The bottom layer containing the LPS was carefully removed by
a pipette. The remaining solution was re-extracted a second time
by adding 200 µL of ice cold Tris-saturated phenol and following
the steps above.
For LPS Western blot analysis, 15 µL of each sample was
run on a denaturing 4–20% Tris-Glycine gel (Novex) according
to manufacturer’s instructions. Monoclonal antibodies 5C7-
4, 5c-101 and MF15-4 (MyBiosource) recognizing the inner,
outer core and O-specific antigen (OSA) for O5 serotype
were used as the primary antibody, and goat anti-mouse
IgG-HRP (SantaCruz Biotechnology) was used as secondary
antibody. Chemiluminescence detection was carried out using
ClarityTM Western ECL blotting substrate (Biorad), and the blot
was visualized on ImageQuant LAS 500 (GE Healthcare Life
Sciences).
DNA Microarray
A total of four biological replicates of F0 and F1 each were
used. Cells were grown to OD600 = 0.5 (mid-log) and 10 mL
aliquots of culture were treated with 20 mL RNAProtect
bacteria reagent (Qiagen) according to manufacturer’s protocol.
RNA was isolated from these cells using RNAeasy MIDI kit
(Qiagen). RNA was then converted to cDNA using Superscript
II (Invitrogen). The cDNA was fragmented using DNAseI (New
England Biolabs) and then labelled with Genechip DNA labeling
reagent (Affymetrix) and terminal deoxynucleotidyl transferase
(Promega). The hybridization cocktail was prepared using the
GeneChip Hybridization, Wash and Stain Kit (Affymetrix) and
hybridized to a P. aeruginosa genome array (Affymetrix). All
steps performed were carried out according to the respective
manufacturers’ protocol. Arrays were hybridized for 16 h at 50◦C
and then washed and stained with the GeneChip Hybridization,
Wash and Stain Kit (Affymetrix). Data from the arrays were
analyzed using Partek Genomics Suite. A list of differentially
expressed genes (DEGs) was constructed using the criteria of
p < 0.05 (one-way ANOVA) and a fold change (FC) of 1.5. Data
are deposited in the Gene Expression Omnibus (GEO) database
under accession number GSE75654.
Next Generation Sequencing (NGS)
The Puregene kit (Qiagen) was used to isolate genomic DNA
from overnight bacterial cultures, according to manufacturer’s
instructions. The quality of the isolated gDNA was assessed
through Nanodrop (Thermo Scientific). A total of five biological
replicates for F1, four biological replicates for F0 were used.
Genomic library preparation was carried out using Nextera XT
kit (Illumina) and according to manufacturer’s instructions. All
samples were pooled and ran on Mi-Seq (Illumina) in a 2 × 300
run. Raw reads were trimmed and aligned to P. aeruginosa PAO1
reference genome (Stover et al., 2000) using online tools1. The
sequences were also compared with the annotated genome of
P. aeruginosa strain PAO12. Aligned reads were analyzed using
Partek Genomic Suite to identify single nucleotide variations
(SNVs). Only SNVs with a coverage >50, non-reference average
base quality >20, and non-reference average mapping quality
>20 were retained to generate an SNV list.
RESULTS
SCV Phenotype of Derived Strain of F1
Wild-type P. aeruginosa PAO1 (F0) was cultured and infected
with PB1 phage. After overnight incubation at 37◦C and
centrifugation at 225 rpm, the culture was streaked on the
agar plate and further incubated. A number of morphologically
distinctive small colonies was observed (Figure 1A) and a SCV
was isolated (F1) from the plate. To check if SCV phenotype
of F1 was stable, the cells were sub-cultured and plated on agar
plates. Figure 1A shows the colony morphology of F0 and F1
strains after 24 h incubation at 37◦C. F1 colonies consistently
showed the typical small and transparent colonies of an SCV after
subculturing and this phenotype persists after seven passages. It
was hypothesized that there may be variations within the genome
of F1 forming a genomic imprint that allows the SCV phenotype
to be maintained. Since F1 was isolated under the selection
pressure imposed by PB1 phage, it is possible that F1 is resistant
to subsequent bacteriophage treatment. Both F0 and F1 were re-
infected with PB1 and their cell viabilities at 0, 3, 6, and 24 h post
infection were measured, using their uninfected counterparts
as controls (Figure 1B). When F0 is infected with phage, its
viability decreased after 3 h, then increased at 6 h and eventually
attained 109 CFU/ mL after 24 h. In contrast, the viability of
F1 increased steadily, in a manner similar to uninfected F0, to
109 CFU/mL after 24 h, regardless of whether phage was added.
The generation time for F1 strain as determined by OD600
measurement is lower than F0 (Figure 1C), which may suggest
that F1 has a faster growth rate, contradicting previous reports
on SCVs being slow-growing (Proctor et al., 2006). However, cell
1usegalaxy.org
2www.pseudomonas.com
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FIGURE 1 | Morphology and Cell Viability. (A) Bacteria was plated on agar plates and incubated for 24 h at 37◦C; left- F0 (wt); right- F1 (SCV). (B) Bacteria count
at 0, 3, 6, 24 h post infection (p.i.) for F0 and F1 strains. (C) Generation times (time taken for the doubling of population) for F0 and F1 strains, a total of three
biological replicates were carried out. (D) Morphologies of gram-stained F0 and F1 strains, viewed under a 100x objective. (E) Distribution of cell length of 40
replicates each for F0 and F1 strains; Mann–Whitney test. F1 cells are significantly smaller than F0 cells. (F) Antibiotic susceptibility of F0 and F1 strains to gentamicin
(left panels) and ciprofloxacin (right panels). ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005.
viability measurements showed there is no difference in growth
(Figure 1B). This is because F0 and F1 cells have different sizes,
thus producing the dichotomy between optical density and cell
viability (Sutton, 2011). A representative set of 40 cells from each
of F0 and F1 strains were picked for cell length measurement.
As shown in Figures 1D,E, F1 has a distribution of cell lengths
which is noticeably shorter than that of F0. From the Etest results,
there appears to be no difference in gentamicin susceptibility
but an increase in ciprofloxacin susceptibility in F1 (Table 1;
Figure 1F).
Several phenotypic assays (biofilm formation, elastase/
pyocyanin assays, twitching motility, microbial adhesion to
hydrocarbon or MATH assay,) were also carried out to
characterize the other physiological differences between F0 wild-
type and F1 SCV strains. Using crystal violet to quantify biofilm
on 96-wells (Figure 2A), it was found that biofilm formed by
F1 cells on the surface of the wells have a lower absorbance at
620 nm than F0; indicating a lower amount of biofilm formation
by the F1 compared with the F0 cells. The elastase and pyocyanin
TABLE 1 | Antibiotic susceptibility measurement with Etest.
Minimum inhibitory concentration (µg/mL)
Antibiotic F0 F1
Gentamicin 2.000 1.500
Ciprofloxacin 0.094 0.016
assays (Figures 2B,C) detected lower amounts of elastase and
pyocyanin in the supernatant of F1 cultures compared to F0.
Since both elastase and pyocyanin are virulence factors whose
functions include inhibiting the growth of competing microflora,
damaging pulmonary tissues and contributing to P. aeruginosa
persistence in cystic fibrosis patients (Lau et al., 2004), decreased
production of these factors by the phage-resistant F1 could result
in lesser adverse effects if phages were used to treat patients.
The twitching assay (Figure 2D) showed that the twitching zone
of F1 is smaller than that of F1, indicating that F1 cells have
lower surface-associated motility than F0 in 1% agar. The MATH
assay is a measurement of surface hydrophobicity, based on the
partitioning of cells between organic and aqueous phases. H% of
F1 is higher than that of F0 (Figure 2E), suggesting that F1 may
have a more hydrophobic cell surface, which may be attributed to
an increase in surface LPS or changes to LPS structure. From our
Western blot analysis, we observed a different banding pattern for
OSA (formerly known as B-band) between F0 and F1 (Figure 2F).
F0 have a uniform distribution of OSA of different lengths while
F1 seems to possess predominantly OSA of medium length and
low amounts of shorter length OSA while devoid of full length
OSA.
DNA Microarray
To study the differences in gene expression between the wild-
type F0 and SCV F1 strains, bacterial samples at mid-log
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FIGURE 2 | Results for phenotypic assays. (A) Biofilm formation assay of three replicates of F0 and F1 strains; Student’s t-test. F1 cells have a significantly lower
OD260 than F0, indicating fewer attached cells since fewer of them are stained. (B) Elastase assay of five replicates of F0 and F1 strains; Student’s t-test. F1 cells
produce significantly lower elastase specific activity than F0. (C) Pyocyanin production assay of five replicates of F0 and F1 strains, measured concurrently with
elastase activity; Student’s t-test. F1 cells produce significantly lower amount of pyocyanin than F0. (D) Twitch assay for seven replicates of F0 and F1 strains;
Student’s t-test. F1 cells have a significantly lower twitching ability than F0. (E) MATH assay of 12 replicates of F0 and F1 strains; Student’s t-test. F1 cells have a
significantly higher H% than F0 cells. (F) Western blot analysis of LPS preparations from F0 and F1 strains, tested using antibodies for inner, outer core and OSA.
∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005.
growth phase were collected for RNA extraction and cDNA
synthesis for DNA microarray transcriptome analysis. After
array hybridization and scanning, data was normalized using
the Gene Chip (GC) robust multi-array analysis (GCRMA) and
probesets were filtered according to their signal intensity and
standard deviation (Hackstadt and Hess, 2009). Probesets with
low signal (<3.2), constituting noise, and with low standard
deviation (<0.25) were removed, yielding 1566 probesets which
met the threshold for analysis. This represented an average
of 63% of the 5900 open reading frames (ORFs) detected on
the array chip. Using a p-value criteria of <0.05 and a FC
of 1.5 for a DEG, 148 DEGs (Figures 3A,B) were identified
between F0 and F1. The 148 DEGs represented 2.5% of the
total number of ORFs, of which 55 genes were upregulated
while 93 were downregulated (Supplementary Tables S1 and
S2). Annotating these DEGs according to their PseudoCAP
(Pseudomonas community annotation project) class functions
(Figure 3C) revealed that the three largest groups of DEGs
belong to metabolism (30%), protein secretion/transport (28%)
and hypothetical proteins (27%).
An interesting group of genes that were upregulated in F1
are the P. aeruginosa serotype O5 OSA biosynthesis cluster
(Table 2A) – wbpI, wbpH, wbpG, hisF2 and hisF1. OSA acts as
the O-antigen for serotype O5 to which PAO1 belongs. This
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FIGURE 3 | Microarray analysis. (A) Volcano Plot showing the fold change and p-value of the 1566 probesets. For a gene to be differentially expressed, it must
satisfy the criteria of p-value <0.05 and fold change > 1.5 or < −1.5. One hundred and forty-eight differentially expressed genes (DEGs) are shown in red on the
plot. (B) Pie chart showing PseudoCAP functional classification of DEGs, with metabolism, hypothetical proteins and protein secretion forming the majority. (C) Bar
graph showing PseudoCAP functional classification of DEGs sorted according to their expression level.
cluster contains 16 genes that are involved in the synthesis
of LPS and three other genes that are not (Burrows et al.,
1996). This group of genes is also found in serotypes O2,
O16, O18, and O20 which have a structurally related O-antigen
serogroup. Down-regulated genes include those involved in
several amino acid catabolic pathways, such as aromatic amino
acid catabolism (Table 2B) – hpd, hmgA, maiA and fahA and
branched chain amino acid (BCAA) catabolism (Table 2C) -
bkdA2, bkdB, mmsA, mmsB and lpdV and (Figures 4A–D).
We proposed that the amino acids may be required as
TABLE 2A | Up-regulated genes involved in Pseudomonas aeruginosa serotype O5 B-band LPS biosynthesis.
Locus Gene Function Fold Change p-value
PA3148 wbpI Probable UDP-N-acetylglucosamine 2-epimerase 1.8 4.E-02
PA3149 wbpH Probable glycosyltransferase WbpH 2.2 3.E-02
PA3150 wbpG LPS biosynthesis protein WbpG 2.1 2.E-02
PA3151 hisF2 Imidazoleglycerol-phosphate synthase, cyclase Subunit 2.4 1.E-02
PA3152 hisH2 Glutamine amidotransferase 2.3 3.E-03
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TABLE 2B | Down-regulated genes involved in aromatic amino acid catabolism.
Locus Gene Function Fold Change p-value
PA0865 hpd∗ 4-hydroxyphenylpyruvate dioxygenase −4.1 8.E-03
PA0870 phhC Aromatic amino acid aminotransferase −2.2 1.E-02
PA2007 maiA∗ Maleylacetoacetate isomerase −2.7 3.E-02
PA2008 fahA∗ Fumarylacetoacetase −3.2 5.E-03
PA2009 hmgA∗ Homogentisate 1,2-dioxygenase −2.7 2.E-02
TABLE 2C | Down-regulated genes involved in branched chain amino acid catabolism.
Locus Gene Function Fold Change p-value
PA0744 – Probable enoyl-CoA hydratase/isomerase −4.1 1.E-03
PA0745 – Probable enoyl-CoA hydratase/isomerase −5.0 1.E-03
PA0747 – Probable aldehyde dehydrogenase −1.6 4.E-02
PA1984 – NAD + dependent aldehyde dehydrogenase −5.5 9.E-04
PA2000 – Dehydrocarnitine CoA transferase, subunit B −1.6 5.E-02
PA2001 atoB Acetyl-CoA acetyltransferase −1.9 1.E-02
PA2012 gnyA Alpha subunit of geranoyl-CoA carboxylase −2.6 4.E-02
PA2013 gnyH Gamma-carboxygeranoyl-CoA hydratase −2.6 2.E-02
PA2014 gnyB Beta subunit of geranoyl-CoA carboxylase −2.3 2.E-02
PA2247 bkdA1 2-oxoisovalerate dehydrogenase (alpha subunit) −2.7 1.E-02
PA2248 bkdA2∗ 2-oxoisovalerate dehydrogenase (beta subunit) −3.4 4.E-03
PA2249 bkdB∗ Branched-chain alpha-keto acid dehydrogenase (lipoamide component) −3.4 1.E-03
PA2250 lpdV∗ Lipoamide dehydrogenase-Val −3.0 4.E-03
PA2553 – Probable acyl-CoA thiolase −5.6 3.E-03
PA2554 – Probable short-chain dehydrogenase −2.2 1.E-02
PA3569 mmsB∗ 3-hydroxyisobutyrate dehydrogenase −4.3 7.E-04
PA3570 mmsA∗ Methylmalonate-semialdehyde dehydrogenase −4.5 6.E-03
∗Denotes genes that were validated with qPCR.
substrates for other pathways hence they are from being
catabolized.
Identifying Unique F1 Single Nucleotide
Variations by Whole Genome Sequencing
Since the SCV phenotype of F1 is stable, whole genome
sequencing to identify single nucleotide variations (SNVs) was
performed to elucidate the underlying genomic changes in F1
compared to wild-type F0. From the SNV list, we needed to
identify SNVs that were present only in F1 but absent in F0. We
pooled all the SNVs found in F1 and F0 separately and compared
the SNVs. Using this approach, 64 SNVs were identified that were
unique only to F1 (Table 3). These SNVs were located in the
region from PA0717-PA0729 (Figure 5A) with the PseudoCAP
class function of “related to phage, transposon and plasmid.”
Three SNVs were from intergenic regions while 61 were from
coding regions. Of the 61 SNVs, 18 were transversions while the
rest was transitions. Furthermore, 11 of the 61 SNVs in the coding
region, 11 SNVs correspond to non-synonymous mutations
while the remainder 50 SNVs corresponds to synonymous
mutations (Figures 5B,C). It was observed that transversions and
non-synoymous SNVs tend to congregate nearer to the 5′ end of
the region (Figure 5B).
It is puzzling that F1 carried so many synonymous mutations
that led to no change in amino acids in the coded proteins.
Synonymous mutations may affect the regulation of protein
expression at the stage of translation whereby certain codons are
much preferred to code for a particular amino acid. This form
of codon usage bias has been extensively described in Escherichia
coli (Sharp et al., 1988; Pek et al., 2015). Studying codon bias in
P. aeruginosa, Grocock and Sharp (2002) concluded that a weak
codon bias is present in P. aeruginosa and calculated relative
synonymous codon usage (RSCU) values for each codon. Using
their RSCU values, we investigated whether there is a trend of
F1 using preferred codons, as specified by its 50 synonymous
mutations, to code for particular amino acids. Synonymous
SNVs were split into two groups based on whether a less or
more efficient codon for a particular amino acid was used. We
identified 29 SNVs where a preferred codon was used and 22
SNVs where a less-preferred codon was used. For each of these
groups, the proportion for each class of amino acid side chain that
was found in the group was counted. We deduced that aromatic
and BCAAs were preferentially coded using more efficient codons
(Figure 5D). An overview of these findings is presented in
Figure 5D which displays the type of SNV at each position.
To address whether such SNVs are common among all SCVs
after infecting P. aeruginosa with PB1 phage, we isolated four
additional SCVs derived from PB1 infection of F0 and sequenced
their genomes. 55 of the 61 SNVs that were identified in F1 were
also present in these 4 SCVs (Figure 5E).
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TABLE 3 | Single nucleotide variations unique to F1 strain compared to the wild-type.
Locus (No. SNVs) Position Ref base Genotype call Ref amino
acid
Amino
acid call
PseudoCAP class function
PA0719
(3)
789941a
789960
789985a
C
A
C
G
C
A
Ser
Arg
Ser
Arg
Arg
Tyr
Hypothetical Related to phage,
transposon, or
plasmid
PA0720
(11)
790228
790267
790312
790360
790408b
790411b
790447b
790453b
790521a,b
790540b
790580a,b
T
A
A
C
T
G
G
A
T
C
A
C
G
C
T
C
C
A
T
C
T
T
Tyr
Gln
Gly
Ile
Arg
Pro
Gln
Leu
Val
Arg
Thr
Tyr
Gln
Gly
Ile
Arg
Pro
Gln
Leu
Ala
Arg
Ser
DNA replication,
recombination,
modification and repair
Related to phage,
transposon, or
plasmid
Intergenic 790604b C G
PA0724
(4)
791486
791518a
791626a
791651
G
C
G
C
A
A
C
T
Ser
Ala
Gly
Gly
Ser
Asp
Ala
Gly
Related to phage,
transposon, or
plasmid
PA0726
(11)
793023b
793026b
793056
793371
793374
793389
793410
793411a
793432a
793437
793449
C
T
G
C
C
T
T
G
T
C
T
G
C
A
G
T
C
C
A
G
T
C
Pro
Asn
Gln
Leu
Asp
His
Ile
Val
Ser
Tyr
Asp
Pro
Asn
Gln
Leu
Asp
His
Ile
Ile
Ala
Tyr
Asp
Hypothetical Related to phage,
transposon, or
plasmid
PA0727
(19)
794872
794875
795082
795289
795307
795331
795349
795355
795361
795391
795394
795403
795457
795499
795553
795574
795583
795598
795652
G
A
G
C
C
G
C
T
A
G
T
C
G
C
T
T
T
T
T
A
G
T
G
T
A
T
C
G
C
C
T
A
T
C
C
C
C
G
Glu
Val
Arg
Val
Arg
Gln
Arg
Ala
Gly
Gly
Leu
His
Thr
Ala
Tyr
Phe
Arg
Phe
Ala
Glu
Val
Arg
Val
Arg
Gln
Arg
Ala
Gly
Gly
Leu
His
Thr
Ala
Tyr
Phe
Arg
Phe
Ala
Hypothetical Related to phage,
transposon, or
plasmid
PA0728
(10)
795867
796015
796035
796125
796161
796203
796273
796443
796446
796452
G
T
C
A
C
C
T
T
C
T
A
C
T
G
T
T
C
C
T
C
Lys
Leu
Cys
Arg
Asn
Arg
Leu
Phe
Ala
Thr
Lys
Leu
Cys
Arg
Asn
Arg
Leu
Phe
Ala
Thr
Putative enzymes Related to phage,
transposon, or
plasmid
(continued)
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TABLE 3 | Continued
Locus (No. SNVs) Position Ref base Genotype call Ref amino
acid
Amino
acid call
PseudoCAP class function
Intergenic 796789
797040
T
T
G
C
PA0729
(3)
797516
797533
797550
T
T
C
C
C
T
Val
Leu
Ser
Ala
Leu
Ser
Hypothetical
aDenotes a non-synonymous SNV. bDenotes SNVs that are not found in the other 4 SCVs isolated.
DISCUSSION
In this study, SCV were isolated from the surviving population
of wild-type P. aeruginosa PAO1 after 24 h of exposure to
PB1 phage. The SCV isolates were found to be resistant to
further PB1 infection and displayed several phenotypic changes.
Compared to the wild-type F0, the PB1 phage-resistant F1 are
less competent at attaching to surfaces in the biofilm formation
assay (Figure 2A), produces lower amounts of the virulence
factors elastase and pyocyanin (Figures 2B,C), and do not twitch
as much (Figure 2D). Since both attachment and twitching
are important processes in the formation of biofilms (O’Toole
and Kolter, 1998; Ramsey and Whiteley, 2004), F0 would be
expected to have greater biofilm formation than F1. Consistent
with reports on bacterial SCVs, reduced twitching ability is also
associated with smaller colonies on agar (Proctor et al., 2006).
The surface of F1 is also more hydrophobic than F0 (Figure 2E),
allowing F1 cells to aggregate more easily through hydrophobic
FIGURE 4 | Pathway analysis of microarray results. (A) Pathway analysis- 5 genes, phhA, hpd, hmgA, maiA and fahA from the aromatic amino acid catabolism
pathway were downregulated (green). (B) Pathway analysis- 5 genes, bkdA2, bkdB, lpdV, mmsA and mmsB from the branched chain amino acid catabolism
pathway were downregulated (green). (C) A representative qPCR validation of phhA, hpd, hmgA, maiA and fahA, normalized to rpoD. (D) A representative qPCR
validation of bkdA2, bkdB, lpdV, mmsA and mmsB, normalized to rpoD.
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FIGURE 5 | Whole genome sequencing of F1 to identify unique SNVs. (A) Figure showing the distribution of unique F1 strains SNV across the Pf1 prophage
regions. All intergenic regions except those containing SNVs were removed for clarity. Numerical values indicate the number of SNVs found in each gene. Genes of
the same color belongs to the same operon. (B) A schematic showing the size of Pf1 prophage region (∼8 kb) in relation the size of the PAO1 genome (∼6 Mb)
(C) Synoymous SNVs were split into two groups based on whether a less or more efficient codon for a particular amino acid was used in F1 and the type of amino
acid side chains were shown in the pie charts. Aromatic and branched chain amino acids (yellow and blue regions respectively) were preferentially using a more
efficient codon. (D) Diagram showing the attributes of the SNVs found in each locus. (E) Venn diagram showing the distribution of these 64 SNVs across 4 other
SNV isolated from F0. 55 of these SNVs are common to all five strains.
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interactions and hence able to form smaller-sized colonies than
F0, similar to clinical variants reported by Kirisits et al. (2005).
The production of virulence factors, pyocyanin and elastase
(Figures 2D,E) are co-regulated through the las quorum sensing
system (Pearson et al., 1997; Glessner et al., 1999; Sauer et al.,
2002). The lower expression of both factors in F1 may indicate
that the las system is deficient in F1 strains.
From the microarray data, several genes from P. aeruginosa
serotype O5 OSA biosynthesis cluster were found to be
upregulated. OSA is made up of repeating units of sugars which
acts as the serotype specific O antigen (Burrows et al., 1996).
The structure of OSA varies among the different P. aeruginosa
serotypes and PAO1 strain belongs to the O5 serotype. OSA
has a varying chain length based on the number of repeating
units (Rocchetta and Lam, 1997). The chain length of the OSA
is regulated by wzz (Daniels et al., 2002). The expression pattern
of several OSA genes was upregulated in the F1 over the F0
strain (Table 2A), indicating alteration of the structure of OSA
in F1. These observations were supported through Western blot
analysis of LPS preparations using antibodies specific to the inner,
outer core and OSA. The results showed a markedly different
distribution of OSA banding pattern between the two strains.
We observed the absence of high molecular weight OSA and
lower amounts of low molecular weight OSA in the F1 over
the F0 strain. This could have contribute to the lower surface
hydrophobicity observed in the MATH assay which suggest
change in structure of LPS. In the study by Garbe et al. (2010),
they concluded that the receptor for the PB1-like phage JG024 is
a component of the core LPS. Changes to the OSA could play
a role in preventing binding of phage particles and initializing
the infection process. From these results, we can postulate that
differences in surface properties between the strains may prevent
PB1 phage from binding to LPS receptors on F1 surface.
Infection by PB1 phages could have induced a stress response
in the P. aeruginosa that caused the bacteria to accumulate
spontaneous mutations. Phage-driven changes in phenotype
have been previously shown for PP7, a ssRNA, pilus-binding
phage. Similar to PB1, PP7 induces SCVs in P. aeruginosa
(Brockhurst et al., 2005). Under stressful conditions, the SOS
response in bacteria is activated, thus allowing the bacteria to
undergo mutations on a genome wide scale (McKenzie et al.,
2000). Certain regions of the genome tend to be hypermutable,
and indeed, our sequencing results show that SNVs were
predominantly found in the Pf1 prophage region, located at
positions PA0719–PA0729 of the P. aeruginosa genome. This
region originated from a horizontal gene transfer event from
Pf1 filamentous lysogenic phages, to ensure that their genetic
material is preserved in the bacteria, and has an unusually low
GC-content when compared to the rest of the genome. In a study
by Wei et al. (2011), where P. aeruginosa SCV was generated by
exposing wild-type bacteria to high concentrations of gentamicin.
One key difference, however, is that the SCV in our study showed
an increased susceptibility to ciprofloxacin, while theirs showed
an increased resistance to the antibiotic. They also discovered a
silent mutation in the elongation factor tufA in revertant cells
that could be the cause of their increased growth rate. In a
similar fashion, the silent mutations found in the Pf1 region in
this study may contribute to codon bias and resulted in one
or more of the phenotypes observed. Filamentous phage have
been known to exhibit high frequency of mutations which could
explain the presence of SNVs found in the Pf1 region (Kuo
et al., 2000). Previous studies have shown that cells can acquire a
superinfective phenotype, capable of killing cells in P. aeruginosa
biofilms, through mutations in the Pf1 region, (Webb et al., 2003).
Similarly, Pf1 prophage might be involved in the selection of
F1 when F0 was first exposed to PB1 phage. This implicates a
possible role in the Pf1 prophage region of P. aeruginosa for the
generation of the SCV phenotype.
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